专题：Inflammatory Myopathies and Dermatomyositis

This cluster of papers covers the epidemiology, classification, and clinical features of inflammatory myopathies such as dermatomyositis and polymyositis. It includes discussions on autoantibodies, interstitial lung disease, cancer risk, treatment strategies, myositis-specific antibodies, juvenile dermatomyositis, and the association with malignancy.
最新文献
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study

article Full Text OpenAlex

Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report

article Full Text OpenAlex

CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease

article Full Text OpenAlex

Effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in managing hypercholesterolemia post-statin-associated immune-mediated necrotizing myopathy: report of five cases and literature review

review Full Text OpenAlex

BCMA-CAR T-cells in a patient with relapsing idiopathic inflammatory myositis after CD19-CAR T-cells

article Full Text OpenAlex

Devastating Complication of Statins: Statin-Induced Proximal Muscle Myositis, Myonecrosis Post-Coronary Artery Bypass Grafting – a Case Report

article Full Text OpenAlex

Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer

article Full Text OpenAlex

Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1γ–positive juvenile dermatomyositis

letter Full Text OpenAlex

Benign acute childhood myositis in the COVID-19 Era: how does it compare to influenza?

article Full Text OpenAlex

Difficulties in the oncology diagnosis with systemic sclerosis. Сase report

article Full Text OpenAlex

近5年高被引文献
Idiopathic inflammatory myopathies

review Full Text OpenAlex 437 FWCI16.13

New-onset IgG autoantibodies in hospitalized patients with COVID-19

article Full Text OpenAlex 404 FWCI89.953

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies

review Full Text OpenAlex 188 FWCI7.324

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

article Full Text OpenAlex 185 FWCI27.743

Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin

article Full Text OpenAlex 173 FWCI26.229

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

article Full Text OpenAlex 172 FWCI35.969

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

article Full Text OpenAlex 167 FWCI25.052

CD19-targeted CAR T cells in refractory antisynthetase syndrome

letter Full Text OpenAlex 155 FWCI0

Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease

article Full Text OpenAlex 149 FWCI23.203

Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis

review Full Text OpenAlex 143 FWCI5.972